Coegin Pharma AB
COEGIN.NGM operates in the healthcare diagnostics segment, focusing on biotechnology and medical research to develop diagnostic solutions for disease detection and monitoring.
Business. COEGIN.NGM is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through product sales, focusing on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
COEGIN.NGM is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm generates revenue through product sales, focusing on pharmaceuticals and medical research activities. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment-specific breakdowns.
COEGIN.NGM maintains a strong liquidity position, with cash and equivalents amounting to 7,923,000 SEK, which exceeds its total liabilities of 8,599,000 SEK. The company's current ratio of 1.16 indicates a modest ability to cover short-term obligations with current assets. However, the company reported negative operating cash flow of -16,546,000 SEK and free cash flow of -17,593,000 SEK, suggesting ongoing cash burn despite its liquidity reserves.
Profitability metrics for COEGIN.NGM are negative, with a return on equity of -4.32 and a return on assets of -1.54, both significantly below the industry median for biotechnology firms. The company reported a net loss of 20,497,000 SEK, with operating income also in the red at -20,452,000 SEK. These figures indicate that the company is not currently generating returns for shareholders or effectively utilizing its assets to generate profit.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment or geographic diversification increases the company's exposure to market-specific risks.
Looking ahead, COEGIN.NGM is expected to continue experiencing revenue contraction, with no positive growth trajectory identified in the available data. The company's operating cash flow and free cash flow remain negative, and no significant capital expenditures are planned, suggesting a focus on cost control rather than expansion.
Risk factors for COEGIN.NGM include the absence of immediate liquidity or dilution flags, with a low risk of dilution and a low liquidity risk. However, the company's ongoing cash burn and negative profitability metrics suggest a high operational risk. No dilution sources were identified in the available documents.
Recent filings and transcripts do not indicate any material events or strategic shifts for COEGIN.NGM. The company's financial performance remains consistent with its historical trend of negative earnings and cash flow, with no new product launches or market expansions disclosed in the available data.
- COEGIN.NGM has strong liquidity but is experiencing significant cash burn and negative profitability.
- The company's return on equity and return on assets are well below industry norms, indicating poor capital efficiency.
- Revenue and operations are concentrated in a single segment, increasing exposure to market-specific risks.
- No immediate liquidity or dilution risks are present, but ongoing cash burn remains a concern.
- The company is not currently generating positive cash flow or returns for shareholders.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- COEGIN.NGM Market data — financials · 2026-05-27